Trial Of Erlotinib With Or Without PF-3512676 In Advanced Non Small Cell Lung Cancer
Status:
Completed
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
To assess the efficacy and safety of PF-3512676 administered in combination with erlotinib in
patients with advanced EGFR-positive non-small cell lung cancer after failure of at least one
prior chemotherapy regimen.